CAGR Value
- The global biologics contract development and manufacturing organization (CDMO) market size was valued at USD 16.61 billion in 2024 and is expected to reach USD 38.27 billion by 2032, at a CAGR of 11.00% during the forecast period
- The market growth is largely fueled by the growing adoption and technological progress within biologic therapies and advanced manufacturing technologies, leading to increased outsourcing by pharmaceutical and biotechnology companies to specialized Biologics Contract Development and Manufacturing Organizations (CDMOs). The complexity of biologics production, including monoclonal antibodies, recombinant proteins, and cell and gene therapies, has driven demand for CDMOs with deep technical expertise and regulatory compliance capabilities
- Furthermore, rising demand for cost-effective, scalable, and flexible manufacturing solutions is establishing CDMOs as strategic partners of choice for both large pharma and emerging biotech firms. These converging factors are accelerating the uptake of Biologics CDMO solutions, thereby significantly boosting the industry's growth. CDMOs offering integrated services—from early-stage development and process optimization to clinical and commercial-scale manufacturing—are particularly well-positioned to benefit from the growing biologics pipeline across therapeutic areas such as oncology, autoimmune diseases, and rare disorders
Biologics Contract Development And Manufacturing Organization (CDMO) Market report, businesses can acquire details about market drivers and market restraints which help them to guess about reducing or growing the production of particular product. It also arranges for top to bottom examination of the market for estimating income, return on investment (ROI) and developing business strategies. This Biologics Contract Development And Manufacturing Organization (CDMO) Market research report comprises of the most significant market insights that takes business to the highest level of growth and success. Various trustworthy sources such as journals, websites, and annual reports of the companies, white papers, and mergers have been used for assembling data and information mentioned in this report.
Stay informed with our latest keyword market research covering strategies, innovations, and forecasts. Download full report: https://www.databridgemarketresearch.com/reports/global-biologics-contract-development-and-manufacturing-organization-cdmo-market
Biologics Contract Development And Manufacturing Organization (CDMO) Market Segmentation and Market Companies
Segments
- By Workflow
- Upstream Processing
- Downstream Processing
- By Product
- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins
- Antisense, Polymerase Chain Reaction (PCR) and Nucleic Acid Molecule
- Others
- By Indication
- Oncology
- Infectious Diseases
- Metabolic Diseases
- Immunology Disorders
- Others
The global biologics contract development and manufacturing organization (CDMO) market is segmented based on workflow, product, and indication. In terms of workflow, the market is divided into upstream processing and downstream processing. The product segment includes monoclonal antibodies, vaccines, recombinant proteins, antisense, polymerase chain reaction (PCR), nucleic acid molecule, and others. Furthermore, the indication segment comprises oncology, infectious diseases, metabolic diseases, immunology disorders, and others.
Market Players
- Lonza
- Boehringer Ingelheim International GmbH
- Samsung Biologics
- WuXi Biologics
- Thermo Fisher Scientific Inc.
- AGC Biologics
- Merck KGaA
- Fujifilm Diosynth Biotechnologies U.S.A., Inc.
- Catalent, Inc.
- AbbVie Inc.
Some of the key players in the global biologics contract development and manufacturing organization (CDMO) market include Lonza, Boehringer Ingelheim International GmbH, Samsung Biologics, WuXi Biologics, Thermo Fisher Scientific Inc., AGC Biologics, Merck KGaA, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Catalent, Inc., and AbbVie Inc. These companies play a crucial role in providing end-to-end solutions for the biopharmaceutical industry, from development to manufacturing, to meet the growing demand for biologics.
The global biologics contract development and manufacturing organization (CDMO) market is witnessing significant growth driven by various factors such as the increasing demand for biopharmaceutical products, advancements in biotechnology, and the rising prevalence of chronic diseases worldwide. As the pharmaceutical industry continues to focus on innovative biologic therapies, the need for specialized expertise and infrastructure for the development and manufacturing of biologics has propelled the expansion of the CDMO sector. Companies like Lonza, Boehringer Ingelheim International GmbH, and Samsung Biologics have established themselves as key players in the market, offering a range of services from process development to commercial manufacturing.
One of the emerging trends in the biologics CDMO market is the increasing adoption of single-use technologies in bioprocessing. Single-use systems offer several advantages such as reduced risk of cross-contamination, flexibility in manufacturing operations, and faster turnaround times. This trend is driven by the growing focus on cost-effective and efficient biomanufacturing processes. Companies like Thermo Fisher Scientific Inc. and WuXi Biologics are investing in single-use technologies to enhance their manufacturing capabilities and meet the evolving needs of their biopharmaceutical clients.
Another key trend shaping the biologics CDMO market is the rise of biosimilars development and manufacturing. With many biologic drugs facing patent expirations, there is a growing opportunity for CDMOs to support the development and manufacturing of biosimilars. This trend is particularly evident in the oncology and immunology segments, where biosimilars offer cost-effective treatment options for patients. Companies like Merck KGaA and AGC Biologics are actively involved in biosimilars development, leveraging their expertise in bioprocessing and regulatory compliance to meet the stringent requirements of this segment.
In terms of geographic expansion, the Asia-Pacific region is emerging as a key hub for biologics CDMO activities. Countries like China, South Korea, and India are attracting investments from global players due to their growing biopharmaceutical markets and skilled workforce. Samsung Biologics, a prominent player in the market, has established state-of-the-art manufacturing facilities in South Korea to cater to the increasing demand for biologics manufacturing services. This trend is expected to continue as companies seek to leverage the cost advantages and technical capabilities available in the region.
Overall, the global biologics CDMO market is poised for continued growth driven by factors such as the increasing demand for biopharmaceuticals, advancements in bioprocessing technologies, and the rise of biosimilars development. Key players in the market are focusing on expanding their capabilities, investing in innovative technologies, and expanding their geographic presence to meet the evolving needs of the biopharmaceutical industry. The coming years are likely to witness further consolidation in the market as companies strive to position themselves as preferred partners for biologic drug development and manufacturing.The global biologics contract development and manufacturing organization (CDMO) market is a dynamic and rapidly evolving sector within the biopharmaceutical industry. Key players such as Lonza, Boehringer Ingelheim International GmbH, and Samsung Biologics are leveraging their expertise and infrastructure to meet the increasing demand for biologic therapies. These companies offer end-to-end solutions, from process development to commercial manufacturing, enabling biopharmaceutical companies to bring innovative therapies to market efficiently.
A notable trend in the biologics CDMO market is the widespread adoption of single-use technologies in bioprocessing. This shift towards disposable systems is driven by the advantages they offer in terms of operational flexibility, reduced contamination risks, and faster production turnaround times. Companies like Thermo Fisher Scientific Inc. and WuXi Biologics are investing in single-use technologies to enhance their manufacturing capabilities and better serve their clients in the biopharmaceutical industry.
Another significant trend impacting the market is the increasing focus on biosimilars development and manufacturing. As patents for many biologic drugs expire, there is a growing opportunity for CDMOs to support the production of biosimilars. This trend, particularly prevalent in the oncology and immunology segments, presents cost-effective treatment options for patients and expands the market reach for biopharmaceutical companies. Players like Merck KGaA and AGC Biologics are actively involved in biosimilars development, leveraging their expertise to navigate the regulatory landscape and meet the robust requirements of this segment.
Geographically, the Asia-Pacific region is emerging as a key hub for biologics CDMO activities. Countries such as China, South Korea, and India are attracting investments from global players due to their growing biopharmaceutical markets and skilled workforce. Samsung Biologics, with its cutting-edge manufacturing facilities in South Korea, exemplifies the trend of companies establishing a presence in the region to capitalize on cost advantages and technical capabilities.
In conclusion, the global biologics CDMO market is poised for robust growth driven by factors such as the increasing demand for biopharmaceuticals and the advancements in bioprocessing technologies. Market players are strategically expanding their capabilities, investing in innovative technologies, and seeking geographic diversification to cater to the evolving needs of the industry. Continued consolidation and collaboration among key players are anticipated as the market continues its trajectory towards becoming a crucial enabler of biologic drug development and manufacturing on a global scale.
Frequently Asked Questions About This Report
What does the value chain for the Biologics Contract Development And Manufacturing Organization (CDMO) Market look like?
How are tiered supplier networks managed in the Biologics Contract Development And Manufacturing Organization (CDMO) Market industry?
How are companies diversifying their supply chains to drive growth?
What is the role of third-party logistics (3PL) in the Biologics Contract Development And Manufacturing Organization (CDMO) Market?
What is the total addressable market (TAM) for Biologics Contract Development And Manufacturing Organization (CDMO) Market solutions?
What is the projected valuation for the [Specific Segment] in the Biologics Contract Development And Manufacturing Organization (CDMO) Market by 2033?
What is the projected market size of the Biologics Contract Development And Manufacturing Organization (CDMO) Market in 2025?
What is the growth of the Biologics Contract Development And Manufacturing Organization (CDMO) Market in Tier 2 cities in China?
Which raw material segment currently dominates the Biologics Contract Development And Manufacturing Organization (CDMO) Market?
How are key players expanding their regional footprint in the Biologics Contract Development And Manufacturing Organization (CDMO) Market?
How is the Biologics Contract Development And Manufacturing Organization (CDMO) Market evolving in terms of packaging and delivery?
How is the Digital Twin technology impacting the Biologics Contract Development And Manufacturing Organization (CDMO) Market value chain?
How is the supply chain of the Biologics Contract Development And Manufacturing Organization (CDMO) Market being optimized?
Browse More Reports:
Global Veterinary Hematology Analyzer Market
Global Vinyl Flooring Market
Global Virology Testing Market
Global Visible Light Communication Market
Global Volatile Organic Compound (VOC) Concentrator Market
Global Walking Assist Devices Market
Global Wired Interface Market
Global Wi-Sun Technology Market
Global Woodworking CNC Tools Market
Global Xenon Headlight Market
Global Zig-Bee Automation Market
North America Telehealth Market
Europe Stents Market
Asia-Pacific Mass Spectrometry Devices Market
North America Medical Robots Market
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 1014
Email:- [email protected]"